// App-Quantinova.ai

PD2-06 : Efficacy of abemaciclib based on genomic alterations detected in baseline circulating tumor DNA from the MONARCH 3 study of abemaciclib plus nonsteroidal aromatase inhibitor

Researchers

Presenter

  • Matthew P Goetz

Principal Investigators

  • J. Thaddeus Beck

  • Mario Campone

  • Sara Hurvitz

  • Seock-Ah Im

  • Stephen Johnston

  • Antonio Llombart-Cussac

  • Miguel Martin

  • Joohyuk Sohn

  • Masakazu Toi

  • Lacey M Litchfield

  • Hillary T Graham

  • Hong Wang

  • Sameera R Wijayawardana

  • Valerie M Jansen

  • Angelo Di Leo

Medical Centers

  • Mayo Clinic, Rochester, MN

  • Highlands Oncology Group, Fayetteville, AR

  • Institut de Cancerologie de l'Ouest Paul Papin, Angers, France

  • University of California, Los Angeles, Los Angeles, CA

  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Hospital Arnau Vilanova, Valencia, Spain

  • Instituto de Investigacion Sanitaria Gregorio Maranon, Universidad Complutense, Madrid, Spain

  • Yonsei Cancer Center, Seoul, Korea, Republic of (South)

  • Kyoto University, Kyoto, Japan

  • Eli Lilly and Company, Indianapolis, IN

  • Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

Locations

  • United States

  • France

  • Republic of South Korea

  • United Kingdom

  • Spain

  • Japan

  • Italy

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Circulating DNA

Drug/Treatment

  • Abemaciclib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02246621

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved